Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 27, 2012Journal of Clinical OncologyOpen Access

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AYAnas YounesUniversité Claude Bernard Lyon 1AGAjay K. GopalCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaSSScott E. SmithThe University of Texas Southwestern Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Younes et al. (2012) studied this question.

synapsesocial.com/papers/69d8240805ee2ba81dbef274https://doi.org/10.1200/jco.2011.38.0410
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas2010 · 1,373 citations
  2. 2Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience2008 · 137 citations
  3. 3Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease2003 · 841 citations
  4. 4Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents2006 · 481 citations
  5. 5Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma2006 · 195 citations